Turnstone Biologics Corp. (TSBX)
(Delayed Data from NSDQ)
$0.70 USD
+0.01 (1.15%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.69 -0.01 (-1.71%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TSBX 0.70 +0.01(1.15%)
Will TSBX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TSBX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for TSBX
Turnstone Biologics price target lowered by $2 at BofA, here's why
Piper Sandler Remains a Buy on Turnstone Biologics Corp. (TSBX)
Turnstone Biologics price target lowered by $16.25 at Piper Sandler, here's why
Turnstone Biologics Corp. (TSBX) Gets a Hold from Leerink Partners
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Turnstone Biologics Corp. (TSBX)